Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy

Cancer

Volumn 115, Issue 13, 2009, Pages 2872-2880

  Tu, Shi Ming ^a   Lopez, Adriana ^a   Leibovici, Dan ^a   Bilen, Mehmet A ^a   Evliyaoglu, Ferhat ^a   Aparicio, Ana ^a   Guo, Charles C ^a   Kuban, Deborah A ^a   Johnson, Marcy M ^a   Pisters, Louis L ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer stem cell; Ductal prostate cancer; Endometrioid prostate cancer; Neoadjuvant therapy; Prostatectomy

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CONTROL; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY;

ADENOCARCINOMA; ADULT; AGED; DISEASE PROGRESSION; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 67649615897     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.24326     Document Type: Article

References (21)

1. Assikis VJ, Do KA, Wen S, et al. Clinical and biomarker correlates of androgen-independent, locally aggressive prostate cancer with limited metastatic potential. Clin Cancer Res. 2004;10:6770-6778. (Pubitemid 39383025)
2. Goldenberg SL, Bruchovsky N, Rennie PS, Coppin CM. The combination of cyproterone acetate and low dose diethylstilbestrol in the treatment of advanced prostatic carcinoma. J Urol. 1988;140:1460-1465. (Pubitemid 19003200)
3. Tu S-M, Reyes A, Maa A, et al. Prostate carcinoma with testicular or penile metastases: clinical, pathologic, and immunohistochemical features. Cancer. 2002;94:2610-2617. (Pubitemid 34478075)
4. Melicow MM, Pachter MR. Endometrial carcinoma of prostatic utricle (uterus masculinus). Cancer. 1967;20:1715-1722.
5. Christensen WN, Steinberg G, Walsh PC, Epstein JI. Prostatic duct adenocarcinoma. Findings at radical prostatectomy. Cancer. 1991;67:2118-2124.
6. Dube VE, Farrow GM, Greene LF. Prostatic adenocarcinoma of ductal origin. Cancer. 1973;32:402-409.
7. Eade TN, Al-Saleem T, Horwitz EM, et al. Role of radiotherapy in ductal (endometrioid) carcinoma of the prostate. Cancer. 2007;109:2011-2015. (Pubitemid 46744195)
8. McNeal JE. Anatomy and normal histology of the human prostate. In Foster CS, Bostwick DG, eds. Pathology of the Prostate. Philadelphia, Pa: WB Saunders; 1998; 19-34.
9. Bock BJ, Bostwick DG. Does prostatic ductal adenocarcinoma exist? Am J Surg Pathol. 1999;23:781-785.
10. Bostwick DG, Kindrachuk RW, Rouse RV. Prostatic adenocarcinoma with endometrioid features: clinical, pathologic, and ultrastructural findings. Am J Surg Pathol. 1985; 9:595-609. (Pubitemid 16220660)
11. Ro JY, Ayala AG, Wishnow KI, Ordonez NG. Prostatic duct adenocarcinoma with endometrioid features: immunohistochemical and electron microscopy study. Semin Diagn Pathol. 1988;5:301-311. (Pubitemid 18203243)
12. Brinker DA, Potter SR, Epstein JI. Ductal adenocarcinoma of the prostate diagnosed on needle biopsy: correlation with clinical and radical prostatectomy findings and progression. Am J Surg Pathol. 1999;23:1471-1479.
13. Millar EKA, Sharma NK, Lessells AM. Ductal (endometrioid) adenocarcinoma of the prostate: a clinicopathological study of 16 cases. Histopathology. 1996;29: 11-19. (Pubitemid 26232517)
14. Epstein JI. Prostatic duct adenocarcinoma. In: Silverberg SG, ed. Biopsy Interpretation Series. Philadelphia, Pa: Lippincott- Raven; 1995: 169-177.
15. Mickisch GH, Garin A, van Poppel H, de Prijck L, Sylvester R. European Organisation for Research and Treatment of Cancer (EORTC) Genitourinary Group. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal cell carcinoma: a randomised trial. Lancet. 2001;358:966-970.
16. Flanigan RC, Salmon SE, Blumenstein BA, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001;345:1655-1659. (Pubitemid 33126820)
17. Rapiti E, Verkooijen HM, Vlastos G, et al. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol. 2006;24:2743-2749. (Pubitemid 46630571)
18. Swanson G, Thompson I, Basler J, Crawford ED. Metastatic prostate cancer-does treatment of the primary tumor matter? J Urol. 2006;176(4 pt 1):1292-1298.
19. Ghavamian R, Bergstralh EJ, Blute ML, Slezak J, Zincke H. Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison. J Urol. 1999;161:1223-1228. (Pubitemid 29426122)
20. Zagars GK, Pollack A, von Eschenbach AC. Addition of radiation therapy to androgen ablation improves outcome for subclinically node-positive prostate cancer. Urology. 2001;58: 233-239. (Pubitemid 32728063)
21. Tu S-M, Lin S-H, Logothetis CJ. Stem-cell origin of metastasis and heterogeneity in solid tumours. Lancet Oncol. 2002;3:508-513. (Pubitemid 34863672)